Penn Virginia Corp (PVA) 0.15 $PVA
pSivida Corp. Announces Fourth Quarter and Fiscal Year 2016 Financial Results Release Date and Conference Call Information
GlobeNewswire - Thu Sep 01, 9:00AM CDT
pSivida Corp. (NASDAQ
SDV) (ASX VA), a leader in the development of sustained release drug delivery products primarily for treating eye diseases, today announced its financial results for the fourth quarter and fiscal year 2016 will be released after the market close on Monday, September 12, 2016, followed the same day by a conference call and live webcast scheduled for 4:30 p.m. ET.
PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)
pSivida Announces 13 New Patents Issued or Allowed
GlobeNewswire - Mon Aug 29, 9:00AM CDT
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced the addition of 13 U.S. and foreign issued patents and allowed applications since the start of 2016. This brings the total number of patents issued and applications allowed in the Company's intellectual property portfolio to 42 in the U.S. and 191 in foreign jurisdictions. An additional 108 applications are pending in the U.S. and foreign jurisdictions.
PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)
Topline Results from First Phase 3 Trial of pSivida's Medidur(TM) Presented at ASRS Annual Meeting
GlobeNewswire - Mon Aug 15, 8:00AM CDT
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced that Dr. Glenn J. Jaffe, Robert Machemer Professor of Ophthalmology at Duke University School of Medicine in Durham, NC and the principal investigator on the first of pSivida's two Phase 3 trials of Medidur for recurrent non-infectious uveitis affecting the posterior segment of the eye, presented the topline results from the trial through its six-month primary endpoint and through 12 months of follow-up. Dr. Jaffe's presentation, "A Randomized, Masked, Controlled, Safety and Efficacy Study of an Injectable Fluocinolone Acetonide (FA) Intravitreal Insert in Non-Infectious Uveitis" took place at the Inflammatory and Infectious Disease session of the American Society of Retinal Specialists Annual Meeting, on Sunday, August 14, in San Francisco.
PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)
Primary Endpoint Met in pSivida's Utilization Study of New Medidur(TM) Inserter with Smaller Diameter Needle
GlobeNewswire - Tue Aug 09, 9:16AM CDT
pSivida Corp. (NASDAQ SDV); (ASX VA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced that its utilization study of its new, proprietary 27-gauge inserter for Medidur for posterior uveitis has met its primary endpoint. In the study, 66 percent of injections using the new 27-gauge inserter achieved a satisfactory rating of "Routine," "Easy" or "Very Easy" while only 46 percent of injections utilizing the earlier, larger 25-gauge inserter used in the first Medidur Phase 3 trial met that standard. The results of this study will form part of pSivida's planned U.S. New Drug Application and application for EU marketing authorization for Medidur for posterior uveitis.
PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)
pSivida Names Dario Paggiarino, M.D. as Chief Medical Officer
GlobeNewswire - Wed Aug 03, 7:00AM CDT
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drug delivery products primarily for eye diseases, has named Dario A. Paggiarino, M.D., to the newly-created position of vice president, chief medical officer. Dr. Paggiarino brings more than 25 years' experience in the pharmaceutical industry. His addition strengthens pSivida's clinical development program, following the consolidation of all of its research and development in the U.S.
PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)
pSivida Corp and Hospital for Special Surgery Innovation Center Announce Opening of IND for Sustained-Release Implant for Severe Knee Osteoarthritis
GlobeNewswire - Mon Aug 01, 6:00AM CDT
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drug delivery products for eye diseases, and Hospital for Special Surgery (HSS), America's leading specialty hospital devoted to orthopedics and rheumatology, announce the opening of an investigational new drug application (IND) to begin an investigator-sponsored clinical study of a sustained-release implant to treat severe osteoarthritis (OA) of the knee. The implant is designed to provide long-term pain relief for severe knee OA, which is anticipated to delay the need for knee replacement surgery.
PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)
pSivida Corp. Provides Company Update and Reports Third Quarter FY 2016 Results
GlobeNewswire - Thu May 05, 3:01PM CDT
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today provided a Company update and announced financial results for its third fiscal quarter ended March 31, 2016.
PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)
pSivida CEO to Present at 2016 International Symposium of Ocular Pharmacology and Therapeutics
GlobeNewswire - Wed May 04, 7:00AM CDT
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that Dr. Paul Ashton, president and CEO, will present "Changing the Treatment Paradigm through Innovative Drug Delivery" at the International Symposium of Ocular Pharmacology and Therapeutics (ISOPT) on Sunday, May 8, 2016 in Paris.
OPHT: 51.32 (-1.65), PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)
pSivida's Medidur for Posterior Uveitis Granted Orphan Drug Designation in Europe
GlobeNewswire - Mon May 02, 6:34AM CDT
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that the European Commission granted orphan medicinal product designation to Medidur(TM) for the treatment of chronic non-infectious uveitis of the posterior of the eye (posterior uveitis).
PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)
pSivida Corp. Announces Third Quarter Fiscal Year 2016 Financial Results Release Date and Conference Call Information
GlobeNewswire - Wed Apr 27, 8:00AM CDT
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that its financial results for the third quarter of fiscal year 2016 will be released after the market close on Thursday, May 5, 2016, followed the same day by a conference call and live webcast scheduled for 4:30 p.m. ET.
PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)
pSivida Corp. Provides Company Update and Reports Second Quarter FY 2016 Results
GlobeNewswire - Mon Feb 08, 3:01PM CST
pSivida Corp. (NASDAQ SDV), (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today provided a Company update and announced financial results for its second fiscal quarter ended December 31, 2015.
PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)
pSivida Corp Announces Second Quarter Fiscal Year 2016 Financial Results Release Date and Conference Call Information
GlobeNewswire - Mon Feb 01, 11:15AM CST
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that its financial results for the second quarter of fiscal year 2016 will be released after the market close on Monday, February 8, 2016, followed the same day by a conference call and live webcast scheduled for 4:30 p.m. ET.
PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)
pSivida CEO to Present at 18th Annual Bio CEO & Investor Conference February 9
GlobeNewswire - Thu Jan 28, 9:30AM CST
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drugs for treating eye diseases, today announced that Dr. Paul Ashton, President and CEO, will present at the 18 Annual Bio CEO & Investor Conference, being held at the Waldorf Astoria Hotel in New York City, Monday and Tuesday, February 8 and 9. Dr. Ashton will make his presentation on Tuesday, February 9 at 11 a.m. EST. A webcast of the presentation will be available at the investor relations section of pSivida's website as well as this link: http://www.veracast.com/webcasts/bio/ceoinves...527117.cfm. A replay of the webcast will be available one hour after the conclusion of Dr. Ashton's presentation that day and will be available until May 8, 2016.
ALIM: 1.50 (-0.05), PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)
pSivida Closes $17.8 Million Offering
GlobeNewswire - Wed Jan 13, 6:45AM CST
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced the closing yesterday of the underwritten public offering of 4,440,000 shares of its common stock at a public offering price of $4.00 per share, which included the exercise in full by the underwriters of their option to purchase up to 440,000 additional shares of common stock, reflecting gross proceeds to pSivida of $17.8 million. pSivida expects net proceeds from the offering to equal approximately $16.4 million after fees and expenses. Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE MKT:LTS), and Northland Securities acted as the joint book-running managers for the offering.
PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04), LTS: 2.30 (+0.01)
Penn Virginia Corporation Announces Suspension of Trading and Commencement of NYSE Delisting Procedures; Common Stock Expected to Begin Trading on the OTC Pink
GlobeNewswire - Tue Jan 12, 5:02PM CST
Penn Virginia Corporation (NYSE VA) today announced that it received notification from the New York Stock Exchange (NYSE) that the NYSE had determined to commence proceedings to delist the Company's common stock as a result of the NYSE's determination that the Company's common stock was no longer suitable for listing on the NYSE based on "abnormally low" price levels, pursuant to Section 802.01D of the NYSE's Listed Company Manual. The NYSE also suspended trading in the Company's common stock effective immediately.
PVA: 0.15 (-0.04)
pSivida Announces Pricing of $16 Million Public Offering of Common Stock
GlobeNewswire - Thu Jan 07, 7:20AM CST
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock at a public offering price of $4.00 per share, for gross proceeds of $16.0 million. In addition, pSivida has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 440,000 shares of pSivida's common stock.
PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)
pSivida Announces Proposed Public Offering of Common Stock
GlobeNewswire - Wed Jan 06, 4:57PM CST
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that it intends to offer and sell shares of its common stock in a proposed underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)
pSivida Plans Medidur(TM) EU Marketing Approval Application Based on Single Phase 3 Clinical Trial
GlobeNewswire - Mon Dec 28, 6:15AM CST
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that it plans to file for EU marketing approval of Medidur(TM) for chronic non-infectious uveitis of the posterior segment of the eye (posterior uveitis) based on data from a single pivotal trial as a result of the high statistical significance achieved in its first Phase 3 clinical trial. The U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) advised pSivida that, consistent with the published Points to Consider (PtC) of the European Agency for Evaluation of Medicinal Products, an application for a product treating a condition like posterior uveitis could be based on statistically compelling and clinically relevant results from just one pivotal trial. The MHRA recently provided this specific advice in formal minutes of a meeting with pSivida held on October 29, 2015 (prior to the Company's receipt of topline results for its first Phase 3 clinical trial). With those results now available, pSivida plans to confirm with the MHRA the plan to file for EU marketing approval of Medidur based on one trial.
PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)
pSivida's Medidur(TM) Meets Primary Efficacy Endpoint in Phase 3 Trial: High Statistical Significance in Prevention of Recurrence of Posterior Uveitis (p Less Than 0.00000001)
GlobeNewswire - Tue Dec 22, 6:00AM CST
Statistical Significance in Improvement in Visual Acuity and Reduction in Systemic Therapy
PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)
With Defaults On the Way, Will Big Oil Go Shopping?
Tyler Crowe and Taylor Muckerman, The Motley Fool - Motley Fool - Wed Nov 18, 1:00PM CST
Oil's low prices have stuck around much longer than so many originally thought. Now, more than a year later, we're starting to see companies like Penn Virginia and Magnum Hunter Resources buckle under the pressure. On today's episode of ...
APA: 51.29 (+1.50), PVA: 0.15 (-0.04), APC: 56.49 (+2.95)
pSivida Corp. Announces Fourth Quarter and Fiscal Year 2016 Financial Results Release Date and Conference Call Information
GlobeNewswire - Thu Sep 01, 9:00AM CDT
pSivida Corp. (NASDAQ
SDV) (ASX VA), a leader in the development of sustained release drug delivery products primarily for treating eye diseases, today announced its financial results for the fourth quarter and fiscal year 2016 will be released after the market close on Monday, September 12, 2016, followed the same day by a conference call and live webcast scheduled for 4:30 p.m. ET. PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)
pSivida Announces 13 New Patents Issued or Allowed
GlobeNewswire - Mon Aug 29, 9:00AM CDT
pSivida Corp. (NASDAQ
SDV) (ASX VA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced the addition of 13 U.S. and foreign issued patents and allowed applications since the start of 2016. This brings the total number of patents issued and applications allowed in the Company's intellectual property portfolio to 42 in the U.S. and 191 in foreign jurisdictions. An additional 108 applications are pending in the U.S. and foreign jurisdictions. PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)
Topline Results from First Phase 3 Trial of pSivida's Medidur(TM) Presented at ASRS Annual Meeting
GlobeNewswire - Mon Aug 15, 8:00AM CDT
pSivida Corp. (NASDAQ
SDV) (ASX VA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced that Dr. Glenn J. Jaffe, Robert Machemer Professor of Ophthalmology at Duke University School of Medicine in Durham, NC and the principal investigator on the first of pSivida's two Phase 3 trials of Medidur for recurrent non-infectious uveitis affecting the posterior segment of the eye, presented the topline results from the trial through its six-month primary endpoint and through 12 months of follow-up. Dr. Jaffe's presentation, "A Randomized, Masked, Controlled, Safety and Efficacy Study of an Injectable Fluocinolone Acetonide (FA) Intravitreal Insert in Non-Infectious Uveitis" took place at the Inflammatory and Infectious Disease session of the American Society of Retinal Specialists Annual Meeting, on Sunday, August 14, in San Francisco. PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)
Primary Endpoint Met in pSivida's Utilization Study of New Medidur(TM) Inserter with Smaller Diameter Needle
GlobeNewswire - Tue Aug 09, 9:16AM CDT
pSivida Corp. (NASDAQ
SDV); (ASX VA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced that its utilization study of its new, proprietary 27-gauge inserter for Medidur for posterior uveitis has met its primary endpoint. In the study, 66 percent of injections using the new 27-gauge inserter achieved a satisfactory rating of "Routine," "Easy" or "Very Easy" while only 46 percent of injections utilizing the earlier, larger 25-gauge inserter used in the first Medidur Phase 3 trial met that standard. The results of this study will form part of pSivida's planned U.S. New Drug Application and application for EU marketing authorization for Medidur for posterior uveitis. PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)
pSivida Names Dario Paggiarino, M.D. as Chief Medical Officer
GlobeNewswire - Wed Aug 03, 7:00AM CDT
pSivida Corp. (NASDAQ
SDV) (ASX VA), a leader in the development of sustained release drug delivery products primarily for eye diseases, has named Dario A. Paggiarino, M.D., to the newly-created position of vice president, chief medical officer. Dr. Paggiarino brings more than 25 years' experience in the pharmaceutical industry. His addition strengthens pSivida's clinical development program, following the consolidation of all of its research and development in the U.S. PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)
pSivida Corp and Hospital for Special Surgery Innovation Center Announce Opening of IND for Sustained-Release Implant for Severe Knee Osteoarthritis
GlobeNewswire - Mon Aug 01, 6:00AM CDT
pSivida Corp. (NASDAQ
SDV) (ASX VA), a leader in the development of sustained release drug delivery products for eye diseases, and Hospital for Special Surgery (HSS), America's leading specialty hospital devoted to orthopedics and rheumatology, announce the opening of an investigational new drug application (IND) to begin an investigator-sponsored clinical study of a sustained-release implant to treat severe osteoarthritis (OA) of the knee. The implant is designed to provide long-term pain relief for severe knee OA, which is anticipated to delay the need for knee replacement surgery. PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)
pSivida Corp. Provides Company Update and Reports Third Quarter FY 2016 Results
GlobeNewswire - Thu May 05, 3:01PM CDT
pSivida Corp. (NASDAQ
SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today provided a Company update and announced financial results for its third fiscal quarter ended March 31, 2016. PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)
pSivida CEO to Present at 2016 International Symposium of Ocular Pharmacology and Therapeutics
GlobeNewswire - Wed May 04, 7:00AM CDT
pSivida Corp. (NASDAQ
SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that Dr. Paul Ashton, president and CEO, will present "Changing the Treatment Paradigm through Innovative Drug Delivery" at the International Symposium of Ocular Pharmacology and Therapeutics (ISOPT) on Sunday, May 8, 2016 in Paris. OPHT: 51.32 (-1.65), PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)
pSivida's Medidur for Posterior Uveitis Granted Orphan Drug Designation in Europe
GlobeNewswire - Mon May 02, 6:34AM CDT
pSivida Corp. (NASDAQ
SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that the European Commission granted orphan medicinal product designation to Medidur(TM) for the treatment of chronic non-infectious uveitis of the posterior of the eye (posterior uveitis). PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)
pSivida Corp. Announces Third Quarter Fiscal Year 2016 Financial Results Release Date and Conference Call Information
GlobeNewswire - Wed Apr 27, 8:00AM CDT
pSivida Corp. (NASDAQ
SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that its financial results for the third quarter of fiscal year 2016 will be released after the market close on Thursday, May 5, 2016, followed the same day by a conference call and live webcast scheduled for 4:30 p.m. ET. PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)
pSivida Corp. Provides Company Update and Reports Second Quarter FY 2016 Results
GlobeNewswire - Mon Feb 08, 3:01PM CST
pSivida Corp. (NASDAQ
SDV), (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today provided a Company update and announced financial results for its second fiscal quarter ended December 31, 2015. PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)
pSivida Corp Announces Second Quarter Fiscal Year 2016 Financial Results Release Date and Conference Call Information
GlobeNewswire - Mon Feb 01, 11:15AM CST
pSivida Corp. (NASDAQ
SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that its financial results for the second quarter of fiscal year 2016 will be released after the market close on Monday, February 8, 2016, followed the same day by a conference call and live webcast scheduled for 4:30 p.m. ET. PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)
pSivida CEO to Present at 18th Annual Bio CEO & Investor Conference February 9
GlobeNewswire - Thu Jan 28, 9:30AM CST
pSivida Corp. (NASDAQ
SDV) (ASX VA), a leader in the development of sustained release drugs for treating eye diseases, today announced that Dr. Paul Ashton, President and CEO, will present at the 18 Annual Bio CEO & Investor Conference, being held at the Waldorf Astoria Hotel in New York City, Monday and Tuesday, February 8 and 9. Dr. Ashton will make his presentation on Tuesday, February 9 at 11 a.m. EST. A webcast of the presentation will be available at the investor relations section of pSivida's website as well as this link: http://www.veracast.com/webcasts/bio/ceoinves...527117.cfm. A replay of the webcast will be available one hour after the conclusion of Dr. Ashton's presentation that day and will be available until May 8, 2016. ALIM: 1.50 (-0.05), PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)
pSivida Closes $17.8 Million Offering
GlobeNewswire - Wed Jan 13, 6:45AM CST
pSivida Corp. (NASDAQ
SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced the closing yesterday of the underwritten public offering of 4,440,000 shares of its common stock at a public offering price of $4.00 per share, which included the exercise in full by the underwriters of their option to purchase up to 440,000 additional shares of common stock, reflecting gross proceeds to pSivida of $17.8 million. pSivida expects net proceeds from the offering to equal approximately $16.4 million after fees and expenses. Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE MKT:LTS), and Northland Securities acted as the joint book-running managers for the offering. PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04), LTS: 2.30 (+0.01)
Penn Virginia Corporation Announces Suspension of Trading and Commencement of NYSE Delisting Procedures; Common Stock Expected to Begin Trading on the OTC Pink
GlobeNewswire - Tue Jan 12, 5:02PM CST
Penn Virginia Corporation (NYSE
VA) today announced that it received notification from the New York Stock Exchange (NYSE) that the NYSE had determined to commence proceedings to delist the Company's common stock as a result of the NYSE's determination that the Company's common stock was no longer suitable for listing on the NYSE based on "abnormally low" price levels, pursuant to Section 802.01D of the NYSE's Listed Company Manual. The NYSE also suspended trading in the Company's common stock effective immediately. PVA: 0.15 (-0.04)
pSivida Announces Pricing of $16 Million Public Offering of Common Stock
GlobeNewswire - Thu Jan 07, 7:20AM CST
pSivida Corp. (NASDAQ
SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock at a public offering price of $4.00 per share, for gross proceeds of $16.0 million. In addition, pSivida has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 440,000 shares of pSivida's common stock. PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)
pSivida Announces Proposed Public Offering of Common Stock
GlobeNewswire - Wed Jan 06, 4:57PM CST
pSivida Corp. (NASDAQ
SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that it intends to offer and sell shares of its common stock in a proposed underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)
pSivida Plans Medidur(TM) EU Marketing Approval Application Based on Single Phase 3 Clinical Trial
GlobeNewswire - Mon Dec 28, 6:15AM CST
pSivida Corp. (NASDAQ
SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that it plans to file for EU marketing approval of Medidur(TM) for chronic non-infectious uveitis of the posterior segment of the eye (posterior uveitis) based on data from a single pivotal trial as a result of the high statistical significance achieved in its first Phase 3 clinical trial. The U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) advised pSivida that, consistent with the published Points to Consider (PtC) of the European Agency for Evaluation of Medicinal Products, an application for a product treating a condition like posterior uveitis could be based on statistically compelling and clinically relevant results from just one pivotal trial. The MHRA recently provided this specific advice in formal minutes of a meeting with pSivida held on October 29, 2015 (prior to the Company's receipt of topline results for its first Phase 3 clinical trial). With those results now available, pSivida plans to confirm with the MHRA the plan to file for EU marketing approval of Medidur based on one trial. PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)
pSivida's Medidur(TM) Meets Primary Efficacy Endpoint in Phase 3 Trial: High Statistical Significance in Prevention of Recurrence of Posterior Uveitis (p Less Than 0.00000001)
GlobeNewswire - Tue Dec 22, 6:00AM CST
Statistical Significance in Improvement in Visual Acuity and Reduction in Systemic Therapy
PSDV: 3.70 (-0.07), PVA: 0.15 (-0.04)
With Defaults On the Way, Will Big Oil Go Shopping?
Tyler Crowe and Taylor Muckerman, The Motley Fool - Motley Fool - Wed Nov 18, 1:00PM CST
Oil's low prices have stuck around much longer than so many originally thought. Now, more than a year later, we're starting to see companies like Penn Virginia and Magnum Hunter Resources buckle under the pressure. On today's episode of ...
APA: 51.29 (+1.50), PVA: 0.15 (-0.04), APC: 56.49 (+2.95)
